Testing a new medication for recurring ovarian or peritoneal cancer

This trial studied whether a medication called trametinib could help women whose ovarian or peritoneal cancer came back after initial treatment with chemotherapy. Participants were randomly assigned to either receive this medication as a daily pill, or to receive one of five standard chemotherapy or hormone therapy options chosen by their doctor. Researchers tracked how long the cancer stayed controlled and how well each treatment worked.

Low-grade serous ovarian and peritoneal cancers often come back after the first round of chemotherapy, and doctors need better treatment options for women who have already been through platinum-based chemotherapy. This medication was being tested because early research suggested it might work differently than standard therapies and could help patients whose cancer had returned.